Ras oncogene induces β‐galactoside α2,6‐sialyltransferase (ST6Gal I) via a RalGEF‐mediated signal to its housekeeping promoter

Several oncogenic proteins are known to influence cellular glycosylation. In particular, transfection of codon 12 point mutated H-Ras increases CMP-Neu5Ac: Galbeta1,4GlcNAc alpha2,6-sialyltransferase I (ST6Gal I) activity in rodent fibroblasts. Given that Ras mediates its effects through at least three secondary effector pathways (Raf, RalGEFs and PI3K) and that transcriptional control of mouse ST6Gal I is achieved by the selective use of multiple promoters, we attempted to identify which of these parameters are involved in linking the Ras signal to ST6Gal I gene transcription in mouse fibroblasts. Transformation by human K-Ras or H-Ras (S12 and V12 point mutations, respectively) results in a 10-fold increase in ST6Gal I mRNA, but no alteration in the expression of related sialyltransferases. Using an inducible H-RasV12 expression system, a direct causal link between activated H-Ras expression and elevated ST6Gal I mRNA was demonstrated. The accumulation of the ST6Gal I transcript in response to activated Ras was accompanied by an increase of alpha2,6-sialyltransferase activity and of Neu5Acalpha2,6Gal at the cell surface. Results obtained with H-RasV12 partial loss of function mutants H-RasV12S35 (Raf signal only), H-RasV12C40 (PI3-kinase signal only) and H-RasV12G37 (RalGEFs signal only) suggest that the H-Ras induction of the mouse ST6Gal I gene (Siat1) transcription is primarily routed through RalGEFs. 5'-Rapid amplification of cDNA ends analysis demonstrated that the increase in ST6Gal I mRNA upon H-RasV12 or K-RasS12 transfection is mediated by the Siat1 housekeeping promoter P3-associated 5' untranslated exons.

[1]  P. Delannoy,et al.  Sialyltransferase activity in FR3T3 cells transformed withras oncogene: decreased CMP-Neu5Ac:Galβ1-3GalNAc α-2,3-sialyltransferase , 1993, Glycoconjugate Journal.

[2]  R. deVere White,et al.  Activated ras alleles in human carcinoma of the prostate are rare. , 1991, Cancer research.

[3]  C. Der,et al.  Distinct requirements for Ras oncogenesis in human versus mouse cells. , 2002, Genes & development.

[4]  J. Ewing,et al.  Murine B cell differentiation is accompanied by programmed expression of multiple novel β-galactoside α2,6-sialyltransferase mRNA forms , 2000 .

[5]  M. Monsigny,et al.  Increased α2,6 Sialylation of N-Glycans in a Transgenic Mouse Model of Hepatocellular Carcinoma , 1997 .

[6]  E. Lander,et al.  Gene expression correlates of clinical prostate cancer behavior. , 2002, Cancer cell.

[7]  V. Laudet,et al.  Comparison of sialyl- and α-1,3-galactosyltransferase activity in NIH3T3 cells transformed with ras oncogene: increased β-galactoside α-2,6-sialyltransferase , 1992 .

[8]  E. Hébert,et al.  Galectin‐3 mRNA level depends on transformation phenotype in ras‐transformed NIH 3T3 cells , 1994, Biology of the cell.

[9]  T. Werner,et al.  MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. , 1995, Nucleic acids research.

[10]  M. Tsujimoto,et al.  Comparison of the Enzymatic Properties of Mouse β-Galactoside α2, 6-Sialyltransferases, ST6Gal I and II , 2003 .

[11]  S. Hakomori,et al.  Glycosylation defining cancer malignancy: New wine in an old bottle , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[12]  P. Schlag,et al.  Clinical Relevance of Sialyltransferases ST6GAL-I and ST3GAL-III in Gastric Cancer , 2003, Oncology.

[13]  D. Stéhelin,et al.  High alpha-2,6-sialylation of N-acetyllactosamine sequences in ras-transformed rat fibroblasts correlates with high invasive potential. , 1995, Glycobiology.

[14]  A. Taniguchi,et al.  Transcriptional regulation of human β-galactoside α2,6-sialyltransferase (hST6Gal I) gene during differentiation of the HL-60 cell line , 2000 .

[15]  H. Chao,et al.  Altered mRNA expression of sialyltransferase in squamous cell carcinomas of the cervix. , 2001, Gynecologic oncology.

[16]  D. Santini,et al.  β‐galactoside α2,6 sialyltransferase in human colon cancer: contribution of multiple transcripts to regulation of enzyme activity and reactivity with sambucus nigra agglutinin , 2000, International journal of cancer.

[17]  P. Schlag,et al.  Preparation and characterization of differently aggregated colorectal carcinoma cell subpopulations from surgical specimens. , 1998, Cancer detection and prevention.

[18]  J. Bos.  p21ras: an oncoprotein functioning in growth factor-induced signal transduction. , 1995, European journal of cancer.

[19]  M. Dalziel,et al.  Murine hepatic β-galactoside α2,6-sialyltransferase gene expression involves usage of a novel upstream exon region , 1997, Glycoconjugate Journal.

[20]  J. R. Morris,et al.  Mouse ST6Gal sialyltransferase gene expression during mammary gland lactation. , 2001, Glycobiology.

[21]  J. Neefjes,et al.  Ras (proto)oncogene induces N‐linked carbohydrate modification: temporal relationship with induction of invasive potential. , 1988, The EMBO journal.

[22]  J. Dennis,et al.  Oncogenes conferring metastatic potential induce increased branching of Asn-linked oligosaccharides in rat2 fibroblasts. , 1989, Oncogene.

[23]  P. Schlag,et al.  Cell surface α2,6-sialylation affects adhesion of breast carcinoma cells , 2002 .

[24]  S. Bellis,et al.  Ras oncogene directs expression of a differentially sialylated, functionally altered β1 integrin , 2003, Oncogene.

[25]  V. Laudet,et al.  The c-Ha-ras Oncogene Induces Increased Expression of β-Galactoside α-2,6-Sialyltransferase in Rat Fibroblast (FR3T3) Cells , 1992 .

[26]  D. Woods,et al.  Regulation of the p53 pathway by Ras, the plot thickens. , 2001, Biochimica et biophysica acta.

[27]  H. Chao,et al.  Expression of sialyltransferase family members in cervix squamous cell carcinoma correlates with lymph node metastasis. , 2002, Gynecologic oncology.

[28]  P. Lance,et al.  Suppression of a sialyltransferase by antisense DNA reduces invasiveness of human colon cancer cells in vitro. , 2001, Biochimica et biophysica acta.

[29]  M. Dalziel,et al.  Hepatic acute phase induction of murine β-galactoside α2,6 sialyltransferase (ST6Gal I) is IL-6 dependent and mediated by elevation of Exon H—containing class of transcripts , 1999 .

[30]  L. Hornez,et al.  Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in human breast cancer. , 1998, Cancer research.

[31]  A. Groth,et al.  Ras-inducible immortalized fibroblasts: focus formation without cell cycle deregulation , 2002, Oncogene.

[32]  J. Azizkhan,et al.  Transcription from TATA-less promoters: dihydrofolate reductase as a model. , 1993, Critical reviews in eukaryotic gene expression.

[33]  J. Paulson,et al.  Sialylation of glycoprotein oligosaccharides N-linked to asparagine. Enzymatic characterization of a Gal beta 1 to 3(4)GlcNAc alpha 2 to 3 sialyltransferase and a Gal beta 1 to 4GlcNAc alpha 2 to 6 sialyltransferase from rat liver. , 1982, The Journal of biological chemistry.

[34]  M. Glick,et al.  Change in glycosylation of membrane glycoproteins after transfection of NIH 3T3 with human tumor DNA. , 1984, Cancer research.

[35]  P M Schlag,et al.  Glycosyltransferase expression in human colonic tissue examined by oligonucleotide arrays. , 2003, Biochimica et biophysica acta.

[36]  J. Marth,et al.  Immune regulation by the ST6Gal sialyltransferase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Tsujimoto,et al.  Characterization of the Second Type of Human β-Galactoside α2,6-Sialyltransferase (ST6Gal II), Which Sialylates Galβ1,4GlcNAc Structures on Oligosaccharides Preferentially , 2002, The Journal of Biological Chemistry.

[38]  W. Kemmner,et al.  Enhanced activity of CMP-NeuAc:Galβ1-4GlcNAc:α2,6-sialyltransferase in metastasizing human colorectal tumor tissue and serum of tumor patients , 1993 .

[39]  K. Hård,et al.  N-linked oligosaccharide changes with oncogenic transformation require sialylation of multiantennae. , 1989, European journal of biochemistry.

[40]  P. Thomas,et al.  Differential expression of alpha2,6-sialyltransferase in colon tumors recognized by a monoclonal antibody. , 1998, Hybridoma.

[41]  G. Clark,et al.  The importance of being K-Ras. , 2000, Cellular signalling.

[42]  P. Warne,et al.  Role of Phosphoinositide 3-OH Kinase in Cell Transformation and Control of the Actin Cytoskeleton by Ras , 1997, Cell.

[43]  N. Shaper,et al.  The increased level of beta1,4-galactosyltransferase required for lactose biosynthesis is achieved in part by translational control. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Wigler,et al.  Multiple ras functions can contribute to mammalian cell transformation , 1995, Cell.

[45]  L. Liotta,et al.  Signal Pathways Which Promote Invasion and Metastasis: Critical and Distinct Contributions of Extracellular Signal-Regulated Kinase and Ral-Specific Guanine Exchange Factor Pathways , 2001, Molecular and Cellular Biology.

[46]  J. Lau,et al.  Transcription of the β-galactoside α2,6-sialyltransferase gene in B lymphocytes is directed by a separate and distinct promoter† , 1996 .

[47]  F. Miller,et al.  Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. , 1983, Invasion & metastasis.

[48]  E. Smeland,et al.  Characterization of a promoter region supporting transcription of a novel human β-galactoside α-2,6-sialyltransferase transcript in HepG2 cells☆ , 1995 .

[49]  J. Bolscher,et al.  Enzymatic amplification involving glycosyltransferases forms the basis for the increased size of asparagine-linked glycans at the surface of NIH 3T3 cells expressing the N-ras proto-oncogene. , 1991, The Journal of biological chemistry.